KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $146.5 million.

  • Acadia Pharmaceuticals' Gains from Investment Securities was N/A to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $146.5 million for FY2024, which is 781.24% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $146.5 million for FY2024, which was up 781.24% from $16.6 million recorded in FY2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Gains from Investment Securities peaked at $146.5 million during FY2024, and registered a low of $15.1 million during FY2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $16.6 million (2023), whereas its average is $59.8 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Gains from Investment Securities fell by 8.25% in 2021, and later surged by 781.24% in 2024.
  • Acadia Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $16.4 million in 2020, then declined by 8.25% to $15.1 million in 2021, then climbed by 8.31% to $16.3 million in 2022, then grew by 1.75% to $16.6 million in 2023, then surged by 781.24% to $146.5 million in 2024.